|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2011-6-20
|
|
pubmed:abstractText |
Hydroxyurea (HU) is the first approved pharmacological treatment of sickle cell anemia (SCA). The objectives of this study were to develop population pharmacokinetic(PK)-pharmacodynamic(PD) models for HU in order to characterize the exposure-efficacy relationships and their variability, compare two dosing regimens by simulations and develop some recommendations for monitoring the treatment.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-10214559,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-11768292,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-1244564,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-12531879,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-12609840,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-12672732,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-12695777,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-15255794,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-15985540,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-16214656,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-16906454,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-1690857,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-17145606,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-17299377,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-17994375,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-18318767,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-18367739,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-18458272,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-20566895,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-21575245,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-7715639,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-9082983,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21619673-9592619
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1750-1172
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
30
|
|
pubmed:meshHeading |
pubmed-meshheading:21619673-Adolescent,
pubmed-meshheading:21619673-Adult,
pubmed-meshheading:21619673-Anemia, Sickle Cell,
pubmed-meshheading:21619673-Computer Simulation,
pubmed-meshheading:21619673-Drug Administration Schedule,
pubmed-meshheading:21619673-Female,
pubmed-meshheading:21619673-Humans,
pubmed-meshheading:21619673-Hydroxyurea,
pubmed-meshheading:21619673-Male,
pubmed-meshheading:21619673-Middle Aged,
pubmed-meshheading:21619673-Models, Biological,
pubmed-meshheading:21619673-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.
|
|
pubmed:affiliation |
Université de Lyon, Lyon, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
